{"entity":{"id":"tikva-allocell","kind":"company","name":"Tikva Allocell","aka":[],"tldr":"Tikva Allocell builds ready-made CAR-T cells from healthy donors' T cells that already fight the common Epstein-Barr virus, with an added shield to stop the patient's immune system rejecting them. Its first product targets a protein found on many solid tumours and was preparing for its first trial in 2026.","summary":"Tikva Allocell Pte Ltd is a late-preclinical Singapore company founded by Ivan Horak, with Baylor College of Medicine's Malcolm Brenner, Cliona Rooney and Helen Heslop as co-founders, and holds an exclusive licence to Baylor cell therapy technologies. Its platform starts from allogeneic Epstein-Barr virus-specific T cells (EBVSTs) from healthy donors, which carry low graft-versus-host risk without heavy gene editing, and arms them with an optimised SerpinB9 variant that inhibits granzyme B and caspases to resist host rejection and activation-induced cell death. It also lists an oncolytic virus strategy to modify the tumour microenvironment.\n\nIn July 2026 it closed a USD 8 million Series A led by Kantharos Capital to complete IND-enabling studies of its lead candidate TAVST01, which targets B7-H3, for clinical development in Singapore and the United States. The company names lung, breast, prostate, pancreatic, gastric, triple-negative breast and paediatric cancers as settings where B7-H3 is overexpressed.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.tikvaallocell.com/"},{"label":"Series A press release, July 2026","url":"https://tikvaallocell.com/tikva-allocell-secures-8-million-series-a-financing-to-advance-engineered-off-the-shelf-cell-therapies-for-solid-tumors/"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","immunotherapy"],"technologies":["allogeneic-cell-therapy","car-t","virus-specific-t-cells"],"targets":["b7h3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated. The Series A is the first financing round on the company's press release list; earlier items there are a joint laboratory with A*STAR's Institute of Molecular and Cell Biology and the Baylor licence. No cancer is linked because the lead product has not been assigned an indication."],"hq":"Singapore","country":"SG","companyType":"cell-therapy","website":"https://www.tikvaallocell.com/","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2026,"amountUsd":8000000,"source":"https://tikvaallocell.com/tikva-allocell-secures-8-million-series-a-financing-to-advance-engineered-off-the-shelf-cell-therapies-for-solid-tumors/","note":"Led by Kantharos Capital"}]},"route":"/companies/tikva-allocell/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"virus-specific-t-cells","kind":"technology","name":"Virus-specific T cells","route":"/technologies/virus-specific-t-cells/"}],"target":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"}]}}